for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CASI Pharmaceuticals Inc

CASI.OQ

Latest Trade

1.16USD

Change

-0.02(-1.69%)

Volume

46,594

Today's Range

1.16

 - 

1.22

52 Week Range

1.14

 - 

3.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

CASI Pharmaceuticals Announces Q1 Revenue Of $5.7 Mln

May 13 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS.Q1 REVENUE $5.7 MILLION.EVOMELA Q1 2021 REVENUE CONTINUES UPWARD TREND; POISED TO MEET GREATER THAN 50% REVENUE GROWTH GUIDANCE IN 2021.QTRLY LOSS PER SHARE $0.11.

Casi Pharmaceuticals Announces Pricing Of $32.5 Mln Public Offering Of Common Stock

March 24 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES PRICING OF $32,500,000 PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 15.9 MILLION COMMON SHARES PRICED AT $2.05PER SHARE.

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

March 23 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

Casi Pharmaceuticals Sees FY Revenue Up More Than 50%

Feb 16 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2020 REVENUES AND PROVIDES BUSINESS UPDATES.SEES FY REVENUE UP MORE THAN 50 PERCENT.SEES Q4 2020 REVENUE ABOUT $4.8 MILLION.SEES FY 2020 REVENUE ABOUT $15 MILLION.

Casi Pharmaceuticals Announces Cnct19 (Cd19 Car-T) Receives China Breakthrough Therapy Designation

Dec 23 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) RECEIVES CHINA BREAKTHROUGH THERAPY DESIGNATION.CASI PHARMACEUTICALS - CHINA GRANTED BREAKTHROUGH DESIGNATION TO PARTNER JUVENTAS CELL THERAPY FOR CNCT19.CASI HAS CO-COMMERCIAL RIGHTS TO CNCT19 AND IS A SHAREHOLDER OF JUVENTAS.CASI PHARMACEUTICALS - BREAKTHROUGH DESIGNATION FOR CNCT19 GRANTED BASED ON INITIAL DATA FROM ONGOING PHASE I STUDY.

Casi Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln - SEC Filing

Nov 20 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.

CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results

Nov 9 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 REVENUE $4.2 MILLION VERSUS $2.7 MILLION.INCREASING EVOMELA FULL-YEAR REVENUE GUIDANCE FOR 2020.QTRLY NET LOSS PER SHARE $0.14.Q3 EARNINGS PER SHARE VIEW $-0.06 -- REFINITIV IBES DATA.

Casi Pharmaceuticals Announces Restructuring Of Partnership With Juventas Cell Therapy

Sept 29 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS ANNOUNCES RESTRUCTURING OF PARTNERSHIP WITH JUVENTAS CELL THERAPY LTD.CASI PHARMACEUTICALS INC - CASI RECEIVES CO-COMMERCIAL RIGHTS TO SECOND PIPELINE PRODUCT.CASI PHARMACEUTICALS INC - CASI INCREASES ITS EQUITY POSITION IN JUVENTAS.CASI PHARMACEUTICALS INC - CASI AND JUVENTAS TO CO-COMMERCIALIZE AND CO-MARKET CD19 CAR-T (CNCT19) THERAPY.CASI PHARMACEUTICALS - EFFECTIVE AS OF SEPT 22, JUVENTAS AND SHAREHOLDERS AGREED TO CERTAIN CONDITIONS IN CONNECTION WITH JUVENTAS' SERIES B FINANCING.CASI PHARMACEUTICALS - SUPPLEMENTARY AGREEMENT PROVIDES CASI WITH CO-COMMERCIAL RIGHTS TO A SECOND PIPELINE PRODUCT FROM JUVENTAS.CASI PHARMACEUTICALS INC - JUVENTAS WILL WAIVE RMB 70 MILLION MILESTONE PAYMENT DUE FROM CASI.CASI PHARMACEUTICALS INC - CASI AND JUVENTAS WILL SHARE A PERCENTAGE OF TOTAL NET PROFITS.CASI PHARMACEUTICALS - CASI WUXI BIO WILL INVEST RMB 70 MILLION IN JUVENTAS' SERIES A PLUS EQUITY, RESULTING IN EQUITY OWNERSHIP OF APPROXIMATELY 19.65%.CASI PHARMACEUTICALS - WEI-WU HE AND JAMES HUANG DID NOT PARTICIPATE IN COMMITTEE'S DELIBERATIONS OR APPROVAL OF DEAL.

Casi Pharmaceuticals, Wuxi Jintou Huicun JV Enter Into Construction Project Contract

Sept 2 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS INC - ON AUGUST 27, CO, JV WITH WUXI JINTOU HUICUN INVESTMENT ENTERPRISE ENTERED INTO CONSTRUCTION PROJECT CONTRACT.CASI PHARMACEUTICALS INC - PURSUANT TO CONSTRUCTION CONTRACT, CASI-WUXI WILL PAY A CONTRACT PRICE OF RMB 74.6 MILLION.CASI PHARMACEUTICALS INC - ESTIMATED COMPLETION DATE IS OCTOBER 13, 2023.

CASI Pharmaceuticals Says Unit Entered Into A Loan Agreement With Juventas

Aug 19 (Reuters) - CASI Pharmaceuticals Inc <CASI.O>::CASI PHARMACEUTICALS INC - ON AUG 14, UNIT ENTERED INTO A LOAN AGREEMENT WITH JUVENTAS.CASI PHARMACEUTICALS - UNDER LOAN AGREEMENT, UNIT WILL LEND JUVENTAS UP TO RMB 40 MILLION (ABOUT USD $5.79 MILLION) TO SUPPORT CONTINUED DEVELOPMENT OF CNCT19.CASI PHARMACEUTICALS - LOAN HAS A TERM OF 365 DAYS AND BEARS INTEREST AT RATE OF 20% PER ANNUM.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up